FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290996954> ?p ?o ?g. }

• W4290996954 endingPage "262" @default.
• W4290996954 startingPage "261" @default.
• W4290996954 abstract "Background Psoriatic arthritis (PsA) is characterized by a range of musculoskeletal and extra-articular disease manifestations. Composite indices are valuable tools to assess the multidimensional nature of PsA. The Psoriatic Arthritis Disease Activity Score (PASDAS) 1 provides robust assessment of both joint and skin domains but is cumbersome to use in clinical practice. The Disease Activity Index for Psoriatic Arthritis (DAPSA) 2 is relatively easy to use but does not assess skin disease. Objectives Using pooled data from the phase 3 DISCOVER-1 and DISCOVER-2 studies of guselkumab (GUS) for the treatment of active PsA: 3,4 (1) Describe the rate of achievement of a new composite endpoint combining DAPSA low disease activity (LDA; score ≤14, including remission) and Investigator Global Assessment (IGA) of psoriasis score ≤1 (range=0 [clear] to 4 [severe]); (2) Determine whether earlier (Week [W] 16) DAPSA LDA + IGA ≤1 is predictive of future achievement of minimal disease activity (MDA) or American College of Rheumatology (ACR) 50 response criteria; and (3) Contrast the performance of DAPSA LDA + IGA ≤1 with that of PASDAS LDA (score ≤3.2). Methods Patients (pts) with active PsA despite standard therapies (DISCOVER-1: ≥3 swollen + ≥3 tender joints; CRP ≥0.3 mg/dL; ~30% had prior use of up to 2 TNF inhibitors; DISCOVER-2: ≥5 swollen + ≥5 tender joints; CRP ≥0.6 mg/dL; all pts were biologic-naïve) were randomized 1:1:1 to GUS 100 mg at W0, W4, then Q4W or Q8W; or placebo (PBO) with crossover to GUS Q4W at W24. In both studies, efficacy of GUS vs PBO was compared at W24 (primary endpoint). The number (%) of pts with DAPSA LDA + IGA ≤1 was determined at W24 for pts randomized to GUS or PBO. For all GUS-randomized pts, baseline variables associated with DAPSA LDA + IGA ≤1 and PASDAS LDA at W16 and the predictive value of W16 DAPSA LDA + IGA ≤1 or PASDAS LDA for achieving ACR50, MDA, and DAPSA LDA at W52 were assessed using logistic regression models. Results At W24, DAPSA LDA + IGA ≤1 was met by 37% (277/748) of GUS-treated pts vs 13% (48/372) in the PBO group. At W16, 27% (203/748) of GUS-randomized pts had DAPSA LDA + IGA ≤1, and 22% (164/748) had PASDAS LDA. Among the 73% (545/748) of pts who did not have DAPSA LDA + IGA ≤1 at W16, most (77% [418/545]) had IGA ≤1 but not DAPSA LDA; 4% (23/545) had DAPSA LDA but not IGA ≤1, and 19% (104/545) had neither component. Baseline predictors of DAPSA LDA + IGA ≤1 at W16 were male gender, lower dactylitis score, lower Health Assessment Questionnaire-Disability Index (HAQ-DI) score, lower tender joint count (TJC), and higher Psoriasis Area and Severity Index (PASI) score. Baseline predictors of PASDAS LDA at W16 were younger age, lower dactylitis score, lower HAQ-DI score, lower TJC, and higher PASI score. As shown (Figure 1), pts who had DAPSA LDA + IGA ≤1 and PASDAS LDA at W16 were significantly more likely to achieve ACR50, MDA, and DAPSA LDA at W52 than pts without W16 responses; odds ratios (ORs) for achievement of ACR50, MDA, and DAPSA LDA responses at W52 were similar for pts who had DAPSA LDA + IGA ≤1 and for pts who had PASDAS LDA at W16. ORs for achievement of ACR50 and MDA at W52 were higher for pts who had both DAPSA LDA and IGA ≤1 at W16 (9.5 and 10.7) than for pts who had DAPSA LDA but not IGA ≤1 (6.5 and 3.5) or IGA ≤1 but not DAPSA LDA (1.6 and 1.5). Conclusion DAPSA LDA at W16 predicted future (W52) achievement of the stringent treatment targets of ACR50 and MDA; associations with W52 response were greater when W16 IGA ≤1 was added to DAPSA LDA. DAPSA LDA + IGA ≤1 at W16 as a predictor of W52 ACR50 and MDA response performed similarly to PASDAS LDA. The novel composite of DAPSA LDA + IGA ≤1 may be a reliable predictor of long-term PsA skin and joint response that is more practical to implement than the PASDAS. References [1]Helliwell PS et al. Ann Rheum Dis. 2013;72:986-91. [2]Schoels M et al. Ann Rheum Dis 2010;69:1441-47. [3]Deodhar A et al. Lancet 2020;395:1115-25. [4]Mease PJ et al. Lancet 2020;395:1126-36. Disclosure of Interests Wolf-Henning Boehncke Speakers bureau: AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, and UCB, Consultant of: AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, and UCB, Alice B Gottlieb Consultant of: AnaptsysBio, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb Co., Incyte, GSK, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., UCB, and Dermavant, Grant/research support from: Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Alexis Ogdie Consultant of: Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, Happify Health, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: Abbvie, Pfizer and Novartis and to Forward from Amgen, Olga Ziouzina Consultant of: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, Pfizer, UCB, Celltrion, and Fresenius-Kabi, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Marilise Marrache Shareholder of: Johnson & Johnson, Employee of: Janssen Inc, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB" @default.
• W4290996954 created "2022-08-13" @default.
• W4290996954 creator A5002895469 @default.
• W4290996954 creator A5015084747 @default.
• W4290996954 creator A5016686362 @default.
• W4290996954 creator A5026017748 @default.
• W4290996954 creator A5031141146 @default.
• W4290996954 creator A5053353962 @default.
• W4290996954 creator A5065774384 @default.
• W4290996954 creator A5069140401 @default.
• W4290996954 creator A5072083932 @default.
• W4290996954 creator A5075179140 @default.
• W4290996954 creator A5084697265 @default.
• W4290996954 creator A5087980633 @default.
• W4290996954 date "2022-05-23" @default.
• W4290996954 modified "2023-10-12" @default.
• W4290996954 title "POS0082 A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES" @default.
• W4290996954 doi "https://doi.org/10.1136/annrheumdis-2022-eular.1070" @default.
• W4290996954 hasPublicationYear "2022" @default.
• W4290996954 type Work @default.
• W4290996954 citedByCount "0" @default.
• W4290996954 crossrefType "journal-article" @default.
• W4290996954 hasAuthorship W4290996954A5002895469 @default.
• W4290996954 hasAuthorship W4290996954A5015084747 @default.
• W4290996954 hasAuthorship W4290996954A5016686362 @default.
• W4290996954 hasAuthorship W4290996954A5026017748 @default.
• W4290996954 hasAuthorship W4290996954A5031141146 @default.
• W4290996954 hasAuthorship W4290996954A5053353962 @default.
• W4290996954 hasAuthorship W4290996954A5065774384 @default.
• W4290996954 hasAuthorship W4290996954A5069140401 @default.
• W4290996954 hasAuthorship W4290996954A5072083932 @default.
• W4290996954 hasAuthorship W4290996954A5075179140 @default.
• W4290996954 hasAuthorship W4290996954A5084697265 @default.
• W4290996954 hasAuthorship W4290996954A5087980633 @default.
• W4290996954 hasBestOaLocation W42909969541 @default.
• W4290996954 hasConcept C126322002 @default.
• W4290996954 hasConcept C16005928 @default.
• W4290996954 hasConcept C2776260265 @default.
• W4290996954 hasConcept C2779134260 @default.
• W4290996954 hasConcept C2779786854 @default.
• W4290996954 hasConcept C2780564577 @default.
• W4290996954 hasConcept C71924100 @default.
• W4290996954 hasConceptScore W4290996954C126322002 @default.
• W4290996954 hasConceptScore W4290996954C16005928 @default.
• W4290996954 hasConceptScore W4290996954C2776260265 @default.
• W4290996954 hasConceptScore W4290996954C2779134260 @default.
• W4290996954 hasConceptScore W4290996954C2779786854 @default.
• W4290996954 hasConceptScore W4290996954C2780564577 @default.
• W4290996954 hasConceptScore W4290996954C71924100 @default.
• W4290996954 hasIssue "Suppl 1" @default.
• W4290996954 hasLocation W42909969541 @default.
• W4290996954 hasOpenAccess W4290996954 @default.
• W4290996954 hasPrimaryLocation W42909969541 @default.
• W4290996954 hasRelatedWork W2895404113 @default.
• W4290996954 hasRelatedWork W2904527393 @default.
• W4290996954 hasRelatedWork W2920791236 @default.
• W4290996954 hasRelatedWork W3106538472 @default.
• W4290996954 hasRelatedWork W3110645580 @default.
• W4290996954 hasRelatedWork W3173895359 @default.
• W4290996954 hasRelatedWork W3194750073 @default.
• W4290996954 hasRelatedWork W3196193197 @default.
• W4290996954 hasRelatedWork W4224235547 @default.
• W4290996954 hasRelatedWork W4250277513 @default.
• W4290996954 hasVolume "81" @default.
• W4290996954 isParatext "false" @default.
• W4290996954 isRetracted "false" @default.
• W4290996954 workType "article" @default.